tetano
Editor, Senior Moderator
Vaccine. 2015 Jun 19. pii: S0264-410X(15)00842-7. doi: 10.1016/j.vaccine.2015.06.053. [Epub ahead of print]
[h=1]AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.[/h] Mallett CP[SUP]1[/SUP], Beaulieu E[SUP]2[/SUP], Joly MH[SUP]3[/SUP], Baras B[SUP]4[/SUP], Lu X[SUP]5[/SUP], Liu F[SUP]6[/SUP], Levine MZ[SUP]7[/SUP], Katz JM[SUP]8[/SUP], Innis BL[SUP]9[/SUP], Giannini SL[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Avian H7 is one of several influenza A virus subtypes that have the potential to cause pandemics. Herein we describe preclinical results following administration of an investigational H7N1 inactivated detergent-split virion vaccine adjuvanted with the AS03 Adjuvant System. The adjuvanted H7N1 vaccine was highly immunogenic compared to the non-adjuvanted H7N1 vaccine in unprimed mice with less than 100ng of hemagglutinin antigen per dose. In addition, compared to the non-adjuvanted vaccine, the AS03-adjuvanted H7N1 vaccine also induced robust HI and VN antibody responses that cross-reacted with other H7 subtypes, including recently emerged H7N9 virus. These H7 data from the preclinical mouse model add to the existing H5 data to suggest that AS03 adjuvant technology may be generally effective for formulating antigen-sparing detergent-split virion vaccines against intrinsically sub-immunogenic avian influenza A virus subtypes.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] AS03 Adjuvant System; Avian H7 subtype influenza viruses; H7N1influenza vaccine; Unprimed mouse immunogenicity model
PMID: 26100923 [PubMed - as supplied by publisher] Free full text
[h=1]AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.[/h] Mallett CP[SUP]1[/SUP], Beaulieu E[SUP]2[/SUP], Joly MH[SUP]3[/SUP], Baras B[SUP]4[/SUP], Lu X[SUP]5[/SUP], Liu F[SUP]6[/SUP], Levine MZ[SUP]7[/SUP], Katz JM[SUP]8[/SUP], Innis BL[SUP]9[/SUP], Giannini SL[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Avian H7 is one of several influenza A virus subtypes that have the potential to cause pandemics. Herein we describe preclinical results following administration of an investigational H7N1 inactivated detergent-split virion vaccine adjuvanted with the AS03 Adjuvant System. The adjuvanted H7N1 vaccine was highly immunogenic compared to the non-adjuvanted H7N1 vaccine in unprimed mice with less than 100ng of hemagglutinin antigen per dose. In addition, compared to the non-adjuvanted vaccine, the AS03-adjuvanted H7N1 vaccine also induced robust HI and VN antibody responses that cross-reacted with other H7 subtypes, including recently emerged H7N9 virus. These H7 data from the preclinical mouse model add to the existing H5 data to suggest that AS03 adjuvant technology may be generally effective for formulating antigen-sparing detergent-split virion vaccines against intrinsically sub-immunogenic avian influenza A virus subtypes.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] AS03 Adjuvant System; Avian H7 subtype influenza viruses; H7N1influenza vaccine; Unprimed mouse immunogenicity model
PMID: 26100923 [PubMed - as supplied by publisher] Free full text